Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
NCT05327647Phase 2Recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- Jun 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bicalutamide in non-muscle-invasive bladder cancer (NMIBC), sponsored by CHU de Québec-Université Laval. Started Jun 2022; status: recruiting.
02
Drugs
bicalutamide
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05327647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327647.